Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes Due 2027
Gossamer also expects to grant the underwriters of the common stock offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered, and expects to grant the underwriters of the convertible senior notes offering a 13-day option to purchase up to an additional 15% of the aggregate principal amount of notes offered solely to cover over-allotments.
The notes will be senior, unsecured obligations of Gossamer and will accrue interest payable semi-annually in arrears and will mature on
Gossamer intends to use the combined net proceeds of the offerings to fund research and development of its product candidates and development programs and for working capital and general corporate purposes.
The offerings are subject to market and other conditions, and there can be no assurance as to whether or when the offerings may be completed, or as to the actual size or terms of the offerings. The closing of each offering is not contingent on the closing of the other offering.
The securities described above are being offered by Gossamer pursuant to a shelf registration statement filed by Gossamer with the
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About
Forward-Looking Statements
Gossamer cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Gossamer’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the completion, timing and size of the offerings and the anticipated use of proceeds therefrom, and the grant of the options to purchase additional shares and notes. Such forward-looking statements involve substantial risks and uncertainties that could cause our actual results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Gossamer that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Gossamer’s business, including, without limitation: the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed public offerings, as well as the risks and uncertainties inherent in Gossamer’s business described in the its prior press releases and filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20200518005706/en/
For Investors and Media:
Gossamer Bio Investor Relations
ir@gossamerbio.com
Source: